Sialic Acid Binding Ig-like Lectin 3
"Sialic Acid Binding Ig-like Lectin 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
| Descriptor ID |
D063268
|
| MeSH Number(s) |
D12.776.503.921.400 D23.050.301.264.900.565 D23.101.100.900.565
|
| Concept/Terms |
Sialic Acid Binding Ig-like Lectin 3- Sialic Acid Binding Ig-like Lectin 3
- Sialic Acid Binding Ig like Lectin 3
- CD33 Antigens
- Siglec-3
- CD33 Antigen
- Antigen, CD33
- Glycoprotein gp67
- gp67, Glycoprotein
- Antigens, CD33
|
Below are MeSH descriptors whose meaning is more general than "Sialic Acid Binding Ig-like Lectin 3".
Below are MeSH descriptors whose meaning is more specific than "Sialic Acid Binding Ig-like Lectin 3".
This graph shows the total number of publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in this website by year, and whether "Sialic Acid Binding Ig-like Lectin 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in Profiles.
-
CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Hum Mol Genet. 2014 May 15; 23(10):2729-36.
-
Orbital myeloid sarcoma in an adult with acute myeloid leukemia, FAB M1, and 12p-deletion. Ophthalmic Plast Reconstr Surg. 2013 May-Jun; 29(3):e73-5.
-
Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest. 2008 Jun; 118(6):2269-80.
-
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007 Jan; 21(1):66-71.
-
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 01; 104(7):1442-52.
-
Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer. 2005 Apr 12; 5:38.
-
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002 Sep; 16(9):1627-36.
-
Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia. Clin Lymphoma. 2002 Mar; 2 Suppl 1:S19-23.
-
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 01; 19(13):3244-54.
-
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001 Jun 01; 97(11):3574-80.